Dr. Robert T. Morris, MD

Medicare patients and services

Medicare patients, 2024

268

Services billed

801

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 122 payments worth $111,305 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Michigan →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 8 companies. The companies reported $253,424 in research payments for these studies, mostly to the institutions running them.

• A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
  Genmab U.S., Inc.
• Study name not reported
  Iovance Biotherapeutics, Inc.
• A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
  Karyopharm Therapeutics Inc.
• A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-A…
  AbbVie Inc.
• NCT03108495
  Iovance Biotherapeutics, Inc.
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
  Pharmaand GmbH · Active, not recruiting · NCT03522246
• A phase 3, randomized, double-blind, multicenter study of dostarlimab
  GlaxoSmithKline, LLC.
• ROSY-O Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
  AstraZeneca UK Limited
• SURPASS 3
  Adaptimmune LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gynecologic Oncology clinicians in Detroit

• Ahmad Awada, MD
• Gunter Deppe, MD
• Gunjal Garg, M.D.
• Radhika Gogoi, MD
• Miriana Hijaz, M.D
• Wooshin Kim, M.D.
• Adnan Munkarah, M.D.
• Alexander Paridon, M.D.